MHC II Lung Cancer Vaccines Prime and Boost Tumor-specific CD4(+) T Cells that Cross-React with Multiple Histologic Subtypes of Non-small Cell Lung Cancer Cells

Eitemau Tebyg

• Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells
  gan: Srivastava, Minu K., et al.
  Cyhoeddwyd: (2008)
• The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes
  gan: Thompson, James A., et al.
  Cyhoeddwyd: (2007)
• Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells
  gan: Bosch, Jacobus J., et al.
  Cyhoeddwyd: (2009)
• Lung Cancer Prevalence in Iran by Histologic Subtypes
  gan: Vardanjani, Hossein Molavi, et al.
  Cyhoeddwyd: (2017)
• Histologic subtypes are not associated with the presence of sarcopenia in lung cancer
  gan: Kim, Chang Rae, et al.
  Cyhoeddwyd: (2018)